LAWRENCE, Mass., June 24, 2015 /PRNewswire/ -- NxStage
Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of
dialysis products, is proud to announce that today is the 10th year
anniversary of the Food and Drug Administration's (FDA) clearance
of its revolutionary System One™. In recognition of this milestone,
the Company is celebrating the personal achievements of patients
performing home hemodialysis (HHD) with the NxStage® System One.
This summer-long celebration will promote the significant life
changing benefits made possible with HHD, feature the System One's
market leading technology, and promote NxStage's decade long role
in helping patients regain control of their lives.
Over ten years ago, NxStage set out to innovate a dialysis
treatment paradigm that could provide patients with access to
more therapy options to meet both their clinical and lifestyle
needs. Today, NxStage's System One is the first and only portable
dialysis machine that enables patients to perform dialysis in their
homes or while traveling, during the day or at night while
sleeping. It has been used to perform over ten million treatments
on thousands of patients around the world, changing the way
patients and clinicians think about hemodialysis.
Jenna Smith is a 29-year-old
Seattle resident with a rare
condition called Dense Deposit Disease (DDD) which led to her
kidney failure. Smith tried a range of treatment options for kidney
failure, including a failed transplant from her father and
in-center hemodialysis. She chose HHD with the System One ten years
ago because the in-center treatment regimen posed challenges for
her individual healthcare needs due to the lack of frequency and
flexibility of the therapy. While treating with the System One,
Smith graduated from the University of
Iowa, moved to Oregon,
earned her graduate degree, and now works in 3D digital modeling at
an engineering firm in Seattle.
"The number of personal goals I've achieved over the past 10
years would not have been possible without the NxStage System One,"
said Smith. "I'm extremely thankful to have found home hemodialysis
because my treatment fits into my life whenever and wherever I
want, instead of the other way around."
"A decade after launching the first System One, we continue to
redefine renal care by allowing patients to take back control of
their lives with home hemodialysis treatments tailored to their own
needs," said Joseph E. Turk,
President of NxStage. "We're committed to improving the lives of
dialysis patients with more groundbreaking innovations in the years
ahead."
Visit our Facebook page www.facebook.com/NxStage to read
more inspiring patient stories throughout the summer. If you would
like to share your personal achievements while using the System One
please email our patient marketing team at
patientstories@nxstage.com.
For more information about the System One, home hemodialysis or
home nocturnal hemodialysis, please visit www.nxstage.com.
Despite the health benefits that home hemodialysis may
provide to those with chronic kidney disease, this form of therapy
is not for everyone. The reported benefits of home hemodialysis may
not be experienced by all patients. The risks associated with
hemodialysis treatments in any environment include, but are not
limited to, high blood pressure, fluid overload, low blood
pressure, heart-related issues, and vascular access complications.
The medical devices used in hemodialysis therapies may add
additional risks including air entering the bloodstream and blood
loss due to clotting or accidental disconnection of the blood
tubing set. Certain risks are unique to the home. Treatments at
home are done without the presence of medical personnel and on-site
technical support. Patients and their partners must be trained on
what to do and how to get medical or technical help if
needed.
Additional Risks Associated with Nocturnal Home Hemodialysis
Therapy
The NxStage System One may be used at night while the patient
and care partner are sleeping. Certain risks associated with
hemodialysis treatment are increased when performing nocturnal
therapy due to the length of treatment time and because therapy is
performed while the patient and care partner are sleeping. These
risks include, but are not limited to, blood access disconnects and
blood loss during sleep, blood clotting due to slower blood flow or
increased treatment time or both, and delayed response to alarms
when waking from sleep. Ancillary anticoagulant infusion pumps and
fluid leak detection devices may be used to decrease certain risks
for home hemodialysis treatments performed at any time, but NxStage
requires the use of fluid leak detectors to identify leaks from the
vascular access, Cycler and Cartridge when performing nocturnal
therapy with the NxStage System One.
About the NxStage System One
The NxStage System One is
the first and only truly portable hemodialysis system cleared
specifically by the FDA for home hemodialysis and home
nocturnal hemodialysis. Its simplicity and revolutionary size (just
over a foot tall) are intended to allow convenient use in patients'
homes and give patients the freedom to travel with their therapy.
When combined with the NxStage PureFlow SL Dialysis Preparation
System, patients are able to further simplify, using ordinary tap
water to create dialysis fluid on demand. Unlike conventional
hemodialysis systems, the System One requires no special
infrastructure to operate. Under the guidance of their physician,
patients can use the NxStage System One, with their trained
partners, where, how and when it best meets their needs, including
while they are sleeping - at home or on vacation and at a medically
appropriate treatment frequency. http://www.nxstage.com/.
About NxStage Medical
NxStage Medical
Inc. (Nasdaq: NXTM) is a medical device company, headquartered
in Lawrence, Massachusetts,
USA, that develops, manufactures and markets innovative
products for the treatment of ESRD and acute kidney failure. For
more information on NxStage and its products, please visit the
Company's website at www.nxstage.com.
Forward-Looking Statements
This release contains
"forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995. All statements contained
in this release that are not clearly historical in nature are
forward-looking, and the words "anticipate," "believe," "expect,"
"estimate," "plan," and similar expressions are generally intended
to identify forward-looking statements. Actual results may differ
materially from those indicated by these forward-looking statements
as a result of various important factors including those that are
discussed in NxStage's filings with the Securities and Exchange
Commission, including the Quarterly Report on Form 10-Q for the
quarter ended March 31, 2015. NxStage
is under no obligation to (and expressly disclaims any such
obligation to) update or alter its forward-looking statements,
whether as a result of new information, future events or
otherwise.
Media contact:
Kristen K. Sheppard, Esq.
ksheppard@nxstage.com
Tel: (978) 332-5923
Photo -
http://photos.prnewswire.com/prnh/20150624/225341
Logo -
http://photos.prnewswire.com/prnh/20110503/MM94799LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/nxstage-kicks-off-10th-anniversary-of-innovation-milestone-with-summer-long-celebration-of-patient-life-achievements-300104071.html
SOURCE NxStage Medical, Inc.